Entropy Neurodynamics Limited has released a press release.
Business Update
Filed with ASX ·
On 6ix: 6ix.com/news/business-update-126
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Response to ASX Price Query
- Appendix 4D and Half Year Report for period 31 December 2021
- Response to ASX Query
- Exopharm and AIRM Sign MSA
- Exopharm Gains US Patent for LEAP Technology
Later from Entropy Neurodynamics
- EX1 to Receive over $2.7m in Prepaid R&D Tax Incentive Claim
- EX1 to receive a further $0.48m in prepaid R&D Tax Incentive
- FY2022 Appendix 4E and Annual Report
- Study results indicate exosomes safe for clinical pursuit
- Exopharm Received R&D Tax Incentive Refund
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics